A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia

Abstract

Weperformed a meta-analysis of randomized controlled trials comparing low-molecularweight heparin (LMWH) vs no LMWH in women with inherited thrombophilia and prior late (<10 weeks) or recurrent early (≥10 weeks) pregnancy loss. Eight trials and 483 patients met our inclusion criteria. There was no significant difference in livebirth rates with the use of LMWH compared with no LMWH (relative risk, 0.81; 95% confidence interval, 0.55-1.19; P =.28), suggesting no benefit of LMWH in preventing recurrent pregnancy loss in women with inherited thrombophilia.